Trial Profile
Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Topotecan (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 29 Aug 2012 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.